Jazz Pharmaceuticals plc Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Jazz Pharmaceuticals plc (JAZZ) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $57.33 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2015-02-24
- Jazz Pharmaceuticals plc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2014 was $57.33M, a 73.50% decline from fiscal 2013.
- Jazz Pharmaceuticals plc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2013 was $216.31M, a 17.17% decline from fiscal 2012.
- Jazz Pharmaceuticals plc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2012 was $261.15M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|
| 2014-12-31 | $57.33M 10-K · filed 2015-02-24 |
| 2013-12-31 | $216.31M 10-K · filed 2015-02-24 |
| 2012-12-31 | $261.15M 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |